# EDGAR Filing Document

**Accession Number:** 0001666700
**File Stem:** 0001666700-26-000007
**Filing Date:** 2026-2
**Character Count:** 75161
**Document Hash:** 1196beb2ca214d0763ce9cac50a8ed44
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001666700-26-000007.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001666700-26-000007

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260210

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DuPont de Nemours, Inc.
- **CENTRAL INDEX KEY:** 0001666700
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 811224539
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38196
- **FILM NUMBER:** 26613366

**BUSINESS ADDRESS:**
- **STREET 1:** 974 CENTRE ROAD
- **STREET 2:** BUILDING 730
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805
- **BUSINESS PHONE:** (302) 295-5783

**MAIL ADDRESS:**
- **STREET 1:** 974 CENTRE ROAD
- **STREET 2:** BUILDING 730
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DowDuPont Inc.
- **DATE OF NAME CHANGE:** 20160211

?xml version='1.0' encoding='ASCII'? dd-20260210

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 10, 2026** 

**DuPont de Nemours, Inc.** 

(Exact name of registrant as specified in its charter)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38196** | **81-1224539** |
| (State or other jurisdiction of<br>incorporation) | (Commission file number) | (IRS Employer Identification No.) |

---

974 Centre Road, Building 730 Wilmington, Delaware 19805 <br> (Address of Principal Executive Offices) (Zip Code)

(302) 295-5783

(Registrant's Telephone Number, Including Area Code)

**<u>Not applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | DD | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

------

**Section 2 - Financial Information**

Item 2.02 Results of Operations and Financial Condition.

On February 10, 2026, DuPont de Nemours, Inc. (the "Company") issued a press release, attached as Exhibit 99.1, and incorporated herein by reference, announcing results for the fourth quarter and full year 2025.

The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of Section 18. Furthermore, the information contained in this report shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

**Section 9 - Financial Statements and Exhibits**

Item 9.01 Financial Statements and Exhibits.

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

---

| | |
|:---|:---|
| <u>[99.1](exhibit991enrschedules-4q25.htm)</u> | Press release issued by DuPont de Nemours, Inc. on February 10, 2026, announcing results for the fourth quarter 2025. |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>DUPONT DE NEMOURS, INC.</u>

Registrant

Date: February 10, 2026

---

| | |
|:---|:---|
| By: | /s/ Madeleine G. Barber |
| Name: | Madeleine G. Barber |
| Title: | Vice President of Tax, Controller and Chief Accounting Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**DuPont Reports Fourth Quarter and Full Year 2025 Results**

*Exceeds Fourth Quarter and Full Year 2025 Guidance* 

*Initiates First Quarter and Full Year 2026 Guidance* 

**Fourth Quarter 2025 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;• Net Sales of $1.7 billion were flat; organic sales decreased 1% versus year-ago period including a $30 million, or 2%, headwind from the third quarter timing shift

&nbsp;&nbsp;&nbsp;&nbsp;• GAAP Loss from continuing operations of $(108) million; operating EBITDA of $409 million

&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;GAAP EPS from continuing operations of $(0.27); adjusted EPS of $0.46

&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by operating activities from continuing operations of $87 million, including $228 million of separation-related transaction cost and other payments; transaction-adjusted free cash flow of $228 million

**Full Year 2025 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;• Net Sales of $6.8 billion increased 2%; organic sales increased 2% versus year-ago period

&nbsp;&nbsp;&nbsp;&nbsp;• GAAP Income from continuing operations of $98 million; operating EBITDA of $1.63 billion

&nbsp;&nbsp;&nbsp;&nbsp;• GAAP EPS from continuing operations of $0.21; adjusted EPS of $1.68

&nbsp;&nbsp;&nbsp;&nbsp;• Cash provided by operating activities from continuing operations of $560 million, including $462 million of separation-related transaction cost and other payments; transaction-adjusted free cash flow of $689 million

**WILMINGTON, Del., Feb. 10, 2026 -** DuPont (NYSE: DD) announced its financial results<sup>(1)</sup> for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for the first quarter and full year 2026.

"Our full year results capped a year of strong, disciplined execution" said Lori Koch, DuPont Chief Executive Officer. "Our teams delivered against our commitments in a dynamic macro environment, driving organic growth, margin expansion, double-digit adjusted EPS growth, and strong cash flow generation."

"Exiting the year with this momentum, we are well positioned to continue advancing our strategic priorities centered on driving growth and delivering consistent performance to create value for shareholders, customers and our employees," Koch concluded.

**Fourth Quarter 2025 Consolidated Results**<sup>(1)</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<br>Dollars in millions, unless noted* | **<br>4Q'25** | **<br>4Q'24** | **Change**<br>**vs. 4Q'24** | **Organic Sales** <sup>(2)</sup><br>**vs. 4Q'24** |
| Net sales | $1693 | $1689 | - | (1)% |
| GAAP Income from continuing operations | $(108) | $(291) | 63% |  |
| Operating EBITDA<sup>(2)</sup> | $409 | $395 | 4% |  |
| Operating EBITDA margin<sup>(2)</sup> % | 24.2% | 23.4% | 80 bps |  |
| GAAP EPS from continuing operations | $(0.27) | $(0.70) | 61% |  |
| Adjusted EPS<sup>(2)</sup> | $0.46 | $0.39 | 18% |  |
| Cash provided by operating activities – cont. ops. | $87 | $161 | (46)% |  |
| Transaction-adjusted free cash flow<sup>(2)</sup> | $228 | $119 | 92% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Results and cash flows are presented on a continuing operations basis, now reflecting the Electronics and Aramids businesses as discontinued operations. See page 8 for further information, including the basis of presentation included in this release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Organic sales, operating EBITDA, operating EBITDA margin, adjusted EPS, transaction-adjusted free cash flow and transaction-adjusted free cash flow conversion are non-GAAP measures and only reflect continuing operations. See page 9 for further discussion, including a definition of significant items. Reconciliation to the most directly comparable GAAP measure, including details of significant items begins on page 16 of this communication.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Effective in the fourth quarter of 2025, following the separation of the Electronics business on November 1, 2025, the Company made changes to its management and reporting structure creating two new reportable segments: Healthcare & Water Technologies and Diversified Industrials.

------

<u>Net sales</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales were flat as a 1% decrease in volume was offset by a 1% currency benefit. Price was flat year-over-year. Fourth quarter net sales included an approximately $30 million, or 2%, headwind from the order timing shift into the third quarter related to system cut-over activities in advance of the planned electronics separation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;3% organic sales growth in Healthcare & Water Technologies; 4% organic sales decline in Diversified Industrials.

<u>GAAP Loss from continuing operations</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP Loss/GAAP EPS from continuing operations improved on higher segment earnings and the absence of prior year losses related to interest rate swaps.

<u>Operating EBITDA</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA increased on favorable mix and cost productivity, partially offset by growth investments.

<u>Adjusted EPS</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EPS increased on higher segment earnings and lower interest expense, partially offset by a higher tax rate.

<u>Cash provided by operating activities from continuing operations</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash provided by operating activities from continuing operations in the quarter of $87 million, capital expenditures of $87 million and separation-related transaction cost and other payments of $228 million resulted in transaction-adjusted free cash flow and related conversion of $228 million and 118%, respectively.

**Fourth Quarter 2025 Segment Highlights**

**Healthcare & Water Technologies**<sup>(3)</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<br>Dollars in millions, unless noted* | **<br>4Q'25** | **<br>4Q'24** | **Change**<br>**vs. 4Q'24** | **Organic Sales**<sup>(2)</sup><br>**vs. 4Q'24** |
| Net sales | $821 | $790 | 4% | 3% |
| Operating EBITDA | $255 | $246 | 4% |  |
| Operating EBITDA margin % | 31.1% | 31.1% | - |  |

---

<u>Net sales</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales increased 4% on organic sales growth of 3% and a currency benefit of 1%. Fourth quarter net sales included an approximately $15 million, or 2%, headwind from the order timing shift into the third quarter due to separation-related activities primarily in Water Technologies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Healthcare Technologies** sales up mid-single digits on an organic basis on broad-based growth led by medical packaging and medical devices.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Water Technologies** sales up low-single digits on an organic basis primarily due to strength in industrial water markets.

<u>Operating EBITDA</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA increased on organic growth and productivity, partially offset by growth investments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Operating EBITDA margin of 31.1% was flat year-over-year.

------

**Diversified Industrials**<sup>(3)</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<br>Dollars in millions, unless noted* | **<br>4Q'25** | **<br>4Q'24** | **Change<br>vs. 4Q'24** | **Organic Sales**<sup>(2)</sup><br>**vs. 4Q'24** |
| Net sales | $872 | $899 | (3)% | (4)% |
| Operating EBITDA | $197 | $193 | 2% |  |
| Operating EBITDA margin % | 22.6% | 21.5% | 110 bps |  |

---

<u>Net sales</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales decreased 3% as organic sales declines of 4% were partially offset by a 1% benefit from currency. Fourth quarter net sales included an approximately $15 million, or 2%, headwind from the order timing shift into the third quarter due to separation-related activities primarily in Industrial Technologies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Building Technologies** sales down high-single digits on an organic basis from ongoing weakness in construction markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Industrial Technologies** sales down low-single digits on an organic basis as strength in aerospace was offset by weakness in printing and packaging markets.

<u>Operating EBITDA</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA increased on favorable mix and cost productivity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•&nbsp;&nbsp;&nbsp;&nbsp;Operating EBITDA margin of 22.6% increased 110 basis points.

**Full Year 2025 Consolidated Results**<sup>(1)</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<br>Dollars in millions, unless noted* | <br>**FY'25** | <br>**FY'24** | **Change**<br>**vs. FY'24** | **Organic Sales**<sup>(2)</sup><br>**vs. FY'24** |
| Net sales | $6849 | $6719 | 2% | 2% |
| GAAP Income (loss) from continuing operations | $98 | $(96) | 202% |  |
| Operating EBITDA<sup>(2)</sup> | $1628 | $1531 | 6% |  |
| Operating EBITDA margin<sup>(2)</sup> % | 23.8% | 22.8% | 100 bps |  |
| GAAP EPS from continuing operations | $0.21 | $(0.23) | 191% |  |
| Adjusted EPS<sup>(2)</sup> | $1.68 | $1.45 | 16% |  |
| Cash provided by operating activities – cont. ops. | $560 | $765 | (27)% |  |
| Transaction-adjusted free cash flow<sup>(2)</sup> | $689 | $587 | 17% |  |

---

<u>Net sales</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales increased 2% as a 3% increase in volume was partially offset by a 1% decrease in price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 7% organic sales growth in Healthcare & Water Technologies; 2% organic sales decline in Diversified Industrials.

<u>GAAP Income from continuing operations</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP Income/GAAP EPS from continuing operations increased on higher segment earnings and a lower effective tax rate.

<u>Operating EBITDA</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA increased on organic growth and productivity, partially offset by growth investments.

<u>Adjusted EPS</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EPS increased on higher segment earnings and lower interest expense.

------

<u>Cash provided by operating activities from continuing operations</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash provided by operating activities from continuing operations in the year of $560 million, capital expenditures of $333 million and separation-related transaction cost and other payments of $462 million resulted in transaction-adjusted free cash flow and related conversion of $689 million and 98%, respectively.

**Full Year 2025 Segment Highlights**

**Healthcare & Water Technologies**<sup>(3)</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<br>Dollars in millions, unless noted* | **<br>FY'25** | **<br>FY'24** | **Change**<br>**vs. FY'24** | **Organic Sales**<sup>(2)</sup><br>**vs. FY'24** |
| Net sales | $3233 | $2976 | 9% | 7% |
| Operating EBITDA | $972 | $844 | 15% |  |
| Operating EBITDA margin % | 30.1% | 28.4% | 170 bps |  |

---

<u>Net sales</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales increased 9% on organic sales growth of 7%, a currency benefit of 1% and a portfolio benefit of 1%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ **Healthcare Technologies** sales up high-single digits on an organic basis on broad-based growth led by medical packaging and biopharma.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ **Water Technologies** sales up mid-single digits on an organic basis primarily due to strength in industrial and municipal water markets.

<u>Operating EBITDA</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA increased on organic growth and productivity, partially offset by growth investments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA margin of 30.1% increased 170 basis points.

**Diversified Industrials**<sup>(3)</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<br>Dollars in millions, unless noted* | **<br>FY'25** | **<br>FY'24** | **Change<br>vs. FY'24** | **Organic Sales**<sup>(2)</sup><br>**vs. FY'24** |
| Net sales | $3616 | $3743 | (3)% | (2)% |
| Operating EBITDA | $800 | $839 | (5)% |  |
| Operating EBITDA margin % | 22.1% | 22.4% | (30) bps |  |

---

<u>Net sales</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales decreased 3% on an organic sales decline of 2% and a portfolio headwind of 1%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Building Technologies** sales down mid-single digits on an organic basis from ongoing weakness in construction markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Industrial Technologies** sales up low-single digits on an organic basis driven by growth in aerospace markets.

<u>Operating EBITDA</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA decreased as cost productivity was more than offset by the organic sales decline.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA margin of 22.1% decreased 30 basis points.

------

**2026 Financial Outlook**

---

| | | |
|:---|:---|:---|
| *<br>Dollars in millions, unless noted* | **<br>1Q'26E** | **<br>Full Year 2026E** |
| Net sales | ~$1,670 | $7075 - $7135 |
| Operating EBITDA<sup>(2)</sup> | ~$395 | $1725 - $1755 |
| Adjusted EPS<sup>(2)</sup> | ~$0.48 | $2.25 - $2.30 |

---

"Our fourth quarter and full year results reflect disciplined execution across the company and a continued focus on operational and financial rigor delivering strong cash generation and margin expansion," said Antonella Franzen, DuPont Chief Financial Officer.

"Our 2026 guidance is in line with the medium-term targets communicated at our recent investor day. Our full year net sales guidance assumes about 3% organic growth and a currency tailwind of about 1% versus last year. Our first quarter net sales assumes about 2% organic growth coupled with a currency tailwind of about 2% on a year-over-year basis," Franzen concluded.

------

**Conference Call**

The Company will host a live webcast of its quarterly earnings conference call with investors to discuss its results and business outlook beginning today at 8:00 a.m. ET. The slide presentation that accompanies the conference call will be posted on the DuPont's Investor Relations Events and Presentations page. A replay of the webcast also will be available on the DuPont's Investor Relations Events and Presentations page following the live event.

**About DuPont**

DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and industrial. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

---

| | |
|:---|:---|
| **For further information contact:**<br>**DuPont**<br>**Investors:**<br>Ann Giancristoforo<br>ann.giancristoforo@dupont.com<br>+1 989-294-5890 | <br>**Media:**<br>Dan Turner<br>daniel.a.turner@dupont.com<br>+1 302-299-7628 |

---

DuPont<sup>TM</sup> and all products, unless otherwise noted, denoted with <sup>TM</sup>, <sup>SM</sup> or® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.

------

***Overview***

DuPont de Nemours, Inc. ("DuPont") completed the previously announced separation of its Electronics business (the "Electronics Separation") into an independent public company, Qnity Electronics, Inc. ("Qnity"), by way of the distribution to DuPont's stockholders of record as of October 22, 2025 of all the issued and outstanding common stock of Qnity on November 1, 2025 (the "Qnity Distribution"). As a result, beginning in the fourth quarter of 2025, the financial results of the divested Electronics business are reflected in DuPont's Consolidated Financial Statements as discontinued operations, along with comparative periods.

On August 29, 2025, DuPont announced a definitive agreement to sell the aramids business (the "Aramids Divestiture") to Arclin a portfolio company of a TJC LP, ("TJC") affiliate, in return for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note from TJC in the principal amount of $300 million and a minority equity interest (the "Equity Consideration") valued at $325 million in the future Arclin holding company that will hold the Arclin global materials business and the aramids business being divested. The transaction is expected to close around the end of the first quarter 2026, subject to customary closing conditions and receipt of regulatory approvals. As a result, beginning in the third quarter of 2025, the financial results of the aramids business being divested are reflected in DuPont's Consolidated Financial Statements as discontinued operations, along with comparative periods.

***Cautionary Statement Regarding Forward-looking Statements***

Certain statements in this release may be considered forward-looking statements, within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements often contain words such as "expect", "anticipate", "intend", "plan", "believe", "seek", "see", "will", "would", "target", "outlook", "stabilization", "confident", "preliminary", "initial", "continue", "may", "could", "project", "estimate", "forecast" and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to (i) the ability to realize the intended benefits of the Electronics Separation and Qnity Distribution, including achievement of the intended tax treatment; contractual allocation to, and assumption by Qnity of certain liabilities, including certain legacy liabilities with respect to PFAS; and the possibility of disputes, litigation or unanticipated costs in connection with the Electronics Separation and Distribution; (ii) the ability to timely effect, if at all, the Aramids Divestiture and the impact on DuPont's balance sheet, financial condition and future results of operations; (iii) risks and costs related to the impact of the arrangement to share future eligible PFAS costs by and among DuPont, Corteva and Chemours, including the outcome of pending or future litigation related to PFAS or PFOA, which includes personal injury claims and natural resource damages claims; the extent and cost of ongoing and potential future remediation obligations; and changes in laws and regulations applicable to PFAS chemicals; (iv) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the Electronics Separation, the Aramids Divestiture and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; (v) risks and uncertainties that are outside the Company's control but adversely impact the overall environment in which DuPont, its customers and/or its suppliers operate, including changes in economic, political, regulatory, international trade, geopolitical, military conflicts, capital markets and other external conditions, including pandemics and responsive actions, as well as natural and other disasters or weather-related events; (vi) the ability to offset increases in cost of inputs, including raw materials, energy and logistics; (vii) the risks and uncertainties associated with continuing or expanding trade disputes or restrictions and responsive actions, new or increased tariffs or export controls including on exports to China of U.S.-regulated products and technology; (viii) other risks to DuPont's business and operations, including the risk of impairment; (ix) risks and uncertainties in connection with completing the $2 billion share buyback authorization DuPont announced on November 3, 2025, including timeline, associated costs and the possibility that the authorization may be suspended or discontinued prior to completion; and (x) other risk factors discussed in DuPont's most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

------

**Non-GAAP Financial Measures**

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont's management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these Non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 15. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

**Key Terms**

*<u>Significant Items</u>*

Significant items are items that arise outside the ordinary course of business for the Company, and beginning in the first quarter 2025, includes items for nonconsolidated affiliates, that the Company's management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item's size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. Management believes the update to the definition of significant items to include those related to nonconsolidated affiliates reflects a more accurate measure of the ongoing performance of the investment. There were no significant items associated with nonconsolidated affiliates recorded for the three and twelve month periods ended December 31, 2025 and December 31, 2024.

*<u>Future Reimbursable Indirect Costs</u>*

Indirect costs, such as those related to corporate and shared service functions allocated to the separated Electronics business, the divested Delrin® business and the Aramids business, do not meet the criteria for discontinued operations and are reported within continuing operations in all respective periods presented. The Company has, is, will or expects to be reimbursed in accordance with the applicable transition service agreements ("TSAs") for the portion of indirect costs related to activities the Company is, will or expects to undertake on a transitional basis to support a) the divested Delrin® business, b) Qnity not beyond year end 2027 for services and 2040 for site leases and, c) the Aramids Business post the intended Aramids Divestiture, but not beyond 2028 (such indirect costs "Future Reimbursable Indirect Costs"). Services provided and costs reimbursed in accordance with the applicable TSAs include but are not limited to, costs associated with information technology services/support, product stewardship and regulatory support, facilities services, and shared property lease costs.

Future Reimbursable Indirect Costs do not meet the criteria for discontinued operations and therefore are included in both GAAP Net Income from Continuing Operations and in GAAP Cash provided by operating activities-continuing operations for all periods presented. Future Reimbursable Indirect Costs are excluded from Adjusted Earnings, Operating EBITDA and beginning in the fourth quarter 2025, from Transaction-Adjusted Free Cash Flow, each defined below. Such indirect costs that are not subject to future reimbursement are reported within continuing operations in Corporate & Other and are included within Adjusted Earnings, Operating EBITDA, and Cash provided by operating activities-continuing operations.

*<u>Corporate DDOB Remediation Costs</u>*

Corporate DDOB Remediation Costs are environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines ("Corporate DDOB Remediation Costs"). Subsequent to the spin-off of Qnity and beginning with the fourth quarter of 2025, DDOB Remediation Costs are excluded from Adjusted Earnings and Operating EBITDA, as defined below, to provide better insight into the underlying business performance of the Company. This update was applied for all periods presented.

------

**Non-GAAP Measure Definitions**

*Organic Sales*

Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

*Adjusted Earnings*

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits ("OPEB") credits / costs, Future Reimbursable Indirect Costs and Corporate DDOB Remediation Costs.

Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion.

*Adjusted EPS*

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2026 associated with intangibles to be about $270 million on a pre-tax basis, or approximately $0.50 per share.

*Operating EBITDA, EBITDA Margin & Incremental Margin*

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, Corporate DDOB Remediation Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Incremental Margin is the change in Operating EBITDA divided by the change in Net Sales for the applicable period.

*Adjusted Free Cash Flow & Adjusted Free Cash Flow Conversion* 

Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity. As a result, Adjusted Free Cash Flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of liquidity, cash provided by operating activities from continuing operations. Management believes Adjusted Free Cash Flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. Management notes that there were no exclusions for items that are unusual in nature and/or infrequent in occurrence for the three and twelve-month periods ended December 31, 2025 and December 31, 2024.

Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow divided by Adjusted Earnings. Management uses Adjusted Free Cash Flow Conversion as an indicator of our ability to convert earnings to cash.

*Transaction Adjusted Free Cash Flow & Transaction Adjusted Free Cash Flow Conversion* 

Management believes supplemental non-GAAP financial measures including Transaction-Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow Conversion (each defined below) provide an integral view of information on the Company's underlying business performance during this period of transformational change. Management believes the Electronics Separation and Aramids Divestiture collectively represent a significant transformational change for the Company and separation-related transaction cost payments impact comparability to the Company's continuing operations. Management believes Transaction-Adjusted Free Cash Flow, which may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. These non-GAAP financial measures are not intended to represent residual cash flow for discretionary expenditures since other non-discretionary expenditures, such as mandatory debt service requirements, are not deducted from the measure.

------

Transaction-Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and removing the impact of separation-related transaction costs and other payment and cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity.

Transaction-Adjusted Free Cash Flow Conversion is defined as Transaction-Adjusted Free Cash Flow excluding separation-related transaction costs, divided by Adjusted Earnings.

Separation-related transaction costs and other payments include cash outflows directly associated with the Electronics Separation and the Aramids Divestiture. These costs include advisor and banking fees, payments related to establishing a new capital structure (including fees associated with interest rate swaps), capital expenditures required to facilitate physical asset separation, restructuring payments associated with senior leadership, and Future Reimbursable Indirect Costs, among other expenditures.

Future Reimbursable Indirect Costs are excluded from Adjusted Earnings and Operating EBITDA. To provide comparable data analysis, the Company has also adjusted payments associated with Future Reimbursable Indirect Costs within *Separation-related transaction costs and other payments*. This adjustment is intended to provide insight into the Company's underlying business performance. For the three and twelve months ended December 31, 2025, the Company adjusted $11 million and $70 million, respectively associated with Future Reimbursable Indirect Costs within *Separation-related transaction costs and other payments*.

For the twelve months ended December 31, 2025, the Company paid $123 million in fees associated with the settlement of interest rate swaps related to the 2048 notes, representing the allocated of the fair value of the swaps at the time of settlement, and $21 million in fees associated with the debt exchange. A total of $124 million and $144 million were reflected in Separation-related transaction costs and other payments for the three and twelve month periods ended December 31, 2025, respectively, these amounts related to achieving the post Electronics Separation capital structure.

Additionally, $4 million and $16 million were reflected in *Separation-related transaction costs and other payments* for the three and twelve month periods ended December 31, 2025, respectively, for expenditures incurred to complete the physical separation of shared locations.

Finally, $9 million of restructuring and other separation payments to senior leadership were reflected in *Separation-related transaction costs and other payments* for the three and twelve month periods ended December 31, 2025. These payments were reflected in other cash payments as they related to the establishment of the post-spin leadership structure.

------

**DuPont de Nemours, Inc.**

**Consolidated Statements of Operations**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Three Months Ended<br> December 31,* | *Three Months Ended<br> December 31,* | *Twelve Months Ended <br>December 31,* | *Twelve Months Ended <br>December 31,* |
| In millions, except per share amounts (Unaudited) | *2025* | *2024* | *2025* | *2024* |
| Net sales | $1693 | $1689 | $6849 | $6719 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | 1095 | 1136 | 4486 | 4499 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses | 38 | 51 | 193 | 203 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 262 | 227 | 1019 | 976 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 71 | 76 | 291 | 294 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 94 | 9 | 151 | 57 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition, integration and separation costs | 36 | 59 | 203 | 90 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity in (loss) earnings of nonconsolidated affiliates | (1) |  | (7) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Sundry income (expense) - net | (101) | (246) | 14 | (111) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 61 | 84 | 313 | 366 |
| (Loss) income from continuing operations before income taxes | $(66) | $(199) | $200 | $117 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes on continuing operations | 42 | 92 | 102 | 213 |
| (Loss) income from continuing operations, net of tax | $(108) | $(291) | $98 | $(96) |
| &nbsp;&nbsp;&nbsp;(Loss) income from discontinued operations, net of tax | (12) | 185 | (836) | 834 |
| Net (loss) income | $(120) | $(106) | $(738) | $738 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interests | 6 | 11 | 41 | 35 |
| Net (loss) income available for DuPont common stockholders | $(126) | $(117) | $(779) | $703 |
| Per common share data: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per common share from continuing operations - basic | $(0.27) | $(0.70) | $0.21 | $(0.23) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per common share from discontinued operations - basic | (0.03) | 0.42 | (2.08) | 1.91 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per common share - basic | $(0.30) | $(0.28) | $(1.87) | $1.68 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per common share from continuing operations - diluted | $(0.27) | $(0.70) | $0.21 | $(0.23) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per common share from discontinued operations - diluted | (0.03) | 0.42 | (2.07) | 1.91 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) earnings per common share - diluted | $(0.30) | $(0.28) | $(1.86) | $1.68 |
| Weighted-average common shares outstanding - basic | 413.7 | 418.3 | 417.5 | 419.2 |
| Weighted-average common shares outstanding - diluted | 413.7 | 418.3 | 419.2 | 419.2 |

---

------

**DuPont de Nemours, Inc.**

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| In millions, except share amounts (Unaudited) | *December 31, 2025* | *December 31, 2024* |
| **Assets** |  |  |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $715 | $1792 |
| &nbsp;&nbsp;&nbsp;Restricted cash and cash equivalents | 42 | 6 |
| &nbsp;&nbsp;&nbsp;Accounts and notes receivable - net | 1669 | 1342 |
| &nbsp;&nbsp;&nbsp;Inventories | 1172 | 1130 |
| &nbsp;&nbsp;&nbsp;Prepaid and other current assets | 121 | 125 |
| &nbsp;&nbsp;&nbsp;Assets of discontinued operations | 1856 | 16380 |
| &nbsp;&nbsp;&nbsp;Total current assets | $5575 | $20775 |
| Property, plant and equipment - net of accumulated depreciation (December 31, 2025 - $3,565; December 31, 2024 - $3,477) | 3464 | 3454 |
| Other Assets |  |  |
| &nbsp;&nbsp;&nbsp;Goodwill | 7915 | 7561 |
| &nbsp;&nbsp;&nbsp;Other intangible assets | 2936 | 3178 |
| &nbsp;&nbsp;&nbsp;Restricted cash and cash equivalents - noncurrent |  | 36 |
| &nbsp;&nbsp;&nbsp;Investments and noncurrent receivables | 432 | 418 |
| &nbsp;&nbsp;&nbsp;Deferred income tax assets | 282 | 237 |
| &nbsp;&nbsp;&nbsp;Deferred charges and other assets | 971 | 977 |
| &nbsp;&nbsp;&nbsp;Total other assets | $12536 | $12407 |
| Total Assets | $21575 | $36636 |
| **Liabilities and Equity** |  |  |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Short-term borrowings | $60 | $1848 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 995 | 1054 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 54 | 79 |
| &nbsp;&nbsp;&nbsp;Accrued and other current liabilities | 882 | 784 |
| &nbsp;&nbsp;&nbsp;Liabilities of discontinued operations | 314 | 1731 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | $2305 | $5496 |
| Long-Term Debt | 3134 | 5323 |
| Other Noncurrent Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Deferred income tax liabilities | 405 | 524 |
| &nbsp;&nbsp;&nbsp;Pension and other post-employment benefits - noncurrent | 432 | 432 |
| &nbsp;&nbsp;&nbsp;Other noncurrent obligations | 1196 | 1068 |
| &nbsp;&nbsp;&nbsp;Total other noncurrent liabilities | $2033 | $2024 |
| Total Liabilities | $7472 | $12843 |
| Commitments and contingent liabilities |  |  |
| Stockholders' Equity |  |  |
| &nbsp;&nbsp;&nbsp;Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2025: 409,195,445 shares; 2024: 417,994,343 shares) | 4 | 4 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 38718 | 47922 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (24278) | (23076) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (525) | (1500) |
| &nbsp;&nbsp;&nbsp;Total DuPont stockholders' equity | $13919 | $23350 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | 184 | 443 |
| &nbsp;&nbsp;&nbsp;Total equity | $14103 | $23793 |
| Total Liabilities and Equity | $21575 | $36636 |

---

------

**DuPont de Nemours, Inc.**

**Consolidated Statement of Cash Flows**

---

| | | |
|:---|:---|:---|
|  | *Year Ended December 31,* | *Year Ended December 31,* |
| In millions (Unaudited) | *2025* | *2024* |
| **Operating Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income | $(738) | $738 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Loss) income from discontinued operations | (836) | 834 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | $98 | $(96) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 647 | 635 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision (credit) for deferred income tax and other tax related items | 13 | (92) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Earnings of nonconsolidated affiliates in excess of dividends received | 8 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension benefit cost (credit) | 3 | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Periodic benefit plan contributions | (44) | (43) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net gain on sales, businesses and investments | (3) | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 151 | 57 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation | 38 | 56 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on debt extinguishment | 99 | 74 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate swap (gain) loss | (31) | 138 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate swap termination | (123) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Donatelle contingent earn-out true-up | (19) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other net loss (income) | 36 | (23) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of effects of acquired and divested companies: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable | (201) | (83) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (10) | 61 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 61 | (36) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities, net | (163) | 117 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash provided by operating activities - continuing operations | $560 | $765 |
| **Investing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (333) | (285) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds and adjustments to proceeds from sales of property and businesses, net of cash divested |  | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions of property and businesses, net of cash acquired | (55) | (313) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other investing activities, net | 14 | 43 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash used for investing activities - continuing operations | $(374) | $(562) |
| **Financing Activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in short-term borrowings | 60 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Distribution from Electronics at spin-off | 4100 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments on long-term debt and fees | (4134) | (687) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of common stock and forward contracts | (500) | (500) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of Company stock | 32 | 50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Employee taxes paid for share-based payment arrangements | (26) | (27) |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions to noncontrolling interests | (9) | (5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid to stockholders | (597) | (635) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash transferred to Electronics at spin-off | (664) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of excise tax on purchase of treasury stock | (8) | (21) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other financing activities, net | (4) | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash used for financing activities - continuing operations | $(1750) | $(1826) |
| **Cash Flows from Discontinued Operations** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash provided by operations - discontinued operations | 852 | 1082 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash used for investing activities - discontinued operations | (313) | (287) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash used for financing activities - discontinued operations | (118) | (21) |
| Cash provided by discontinued operations | $421 | $774 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 11 | (62) |
| **Decrease in cash, cash equivalents and restricted cash** | $(1132) | $(911) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash from continuing operations, beginning of period | 1834 | 2755 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash from discontinued operations, beginning of period | 58 | 48 |
| **Cash, cash equivalents and restricted cash at beginning of period** | $1892 | $2803 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash from continuing operations, end of period | 757 | 1834 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents and restricted cash from discontinued operations, end of period | 3 | 58 |
| **Cash, cash equivalents and restricted cash at end of period** | $760 | $1892 |

---

------

**DuPont de Nemours, Inc.**

**Net Sales by Segment and Geographic Region**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Net Sales by Segment and Geographic Region** | *Three Months Ended* | *Three Months Ended* | *Twelve Months Ended* | *Twelve Months Ended* |
| In millions (Unaudited) | *Dec 31, 2025* | *Dec 31, 2024* | *Dec 31, 2025* | *Dec 31, 2024* |
| Healthcare & Water Technologies | $821 | $790 | $3233 | $2976 |
| Diversified Industrials | 872 | 899 | 3616 | 3743 |
| Total | $1693 | $1689 | $6849 | $6719 |
| U.S. & Canada | $839 | $845 | $3415 | $3371 |
| EMEA <sup>1</sup> | 357 | 333 | 1468 | 1379 |
| Asia Pacific <sup>2</sup> | 419 | 431 | 1640 | 1647 |
| Latin America | 78 | 80 | 326 | 322 |
| Total | $1693 | $1689 | $6849 | $6719 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Net Sales Variance by Segment and Geographic Region** | *Three Months Ended December 31, 2025* | *Three Months Ended December 31, 2025* | *Three Months Ended December 31, 2025* | *Three Months Ended December 31, 2025* | *Three Months Ended December 31, 2025* | *Three Months Ended December 31, 2025* |
| **Net Sales Variance by Segment and Geographic Region** | *Local Price & Product Mix* | *Volume* | *Total<br>Organic* | *Currency* | *Portfolio / Other* | ***Total*** |
| Percent change from prior year (Unaudited) | *Local Price & Product Mix* | *Volume* | *Total<br>Organic* | *Currency* | *Portfolio / Other* | ***Total*** |
| Healthcare & Water Technologies | —% | 3% | 3% | 1% | —% | 4% |
| Diversified Industrials |  | (4) | (4) | 1 |  | (3) |
| Total | —% | (1)% | (1)% | 1% | —% | —% |
| U.S. & Canada | 2% | (2)% | —% | (1)% | —% | (1)% |
| EMEA <sup>1</sup> | (1) | 3 | 2 | 5 |  | 7 |
| Asia Pacific <sup>2</sup> | (2) |  | (2) | (1) |  | (3) |
| Latin America | (2) | (1) | (3) |  |  | (3) |
| Total | —% | (1)% | (1)% | 1% | —% | —% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Net Sales Variance by Segment and Geographic Region** | *Twelve Months Ended December 31, 2025* | *Twelve Months Ended December 31, 2025* | *Twelve Months Ended December 31, 2025* | *Twelve Months Ended December 31, 2025* | *Twelve Months Ended December 31, 2025* | *Twelve Months Ended December 31, 2025* |
| **Net Sales Variance by Segment and Geographic Region** | *Local Price & Product Mix* | *Volume* | *Total<br>Organic* | *Currency* | *Portfolio / Other* | ***Total*** |
| Percent change from prior year (Unaudited) | *Local Price & Product Mix* | *Volume* | *Total<br>Organic* | *Currency* | *Portfolio / Other* | ***Total*** |
| Healthcare & Water Technologies | —% | 7% | 7% | 1% | 1% | 9% |
| Diversified Industrials | (1) | (1) | (2) |  | (1) | (3) |
| Total | (1)% | 3% | 2% | —% | —% | 2% |
| U.S. & Canada | —% | 1% | 1% | (1)% | 1% | 1% |
| EMEA <sup>1</sup> | (1) | 4 | 3 | 2 | 1 | 6 |
| Asia Pacific <sup>2</sup> | (1) | 5 | 4 |  | (4) |  |
| Latin America | (2) | 3 | 1 |  |  | 1 |
| Total | (1)% | 3% | 2% | —% | —% | 2% |

---

1. Europe, Middle East and Africa.

2. Net sales attributed to China/Hong Kong, for the three months ended December 31, 2025 and 2024 were $184 million and $188 million, respectively, while for the twelve months ended December 31, 2025 and 2024 net sales attributed to China/Hong Kong were $708 million and $763 million, respectively.

------

**DuPont de Nemours, Inc.**

**Selected Financial Information and Non-GAAP Measures**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Operating EBITDA** **by Segment**  | *Three Months Ended* | *Three Months Ended* | *Twelve Months Ended* | *Twelve Months Ended* |  |  |  |  |  |
| In millions (Unaudited) | *Dec 31, 2025* | *Dec 31, 2024* | *Dec 31, 2025* | *Dec 31, 2024* |  |  |  |  |  |
| Healthcare & Water Technologies | $255 | $246 | $972 | $844 |  |  |  |  |  |
| Diversified Industrials | 197 | 193 | 800 | 839 |  |  |  |  |  |
| Corporate <sup>1</sup> | (43) | (44) | (144) | (152) |  |  |  |  |  |
| Total | $409 | $395 | $1628 | $1531 |  |  |  |  |  |
| 1. Corporate includes expenses of the Corporate function not allocated to specific business in the Company. | 1. Corporate includes expenses of the Corporate function not allocated to specific business in the Company. | 1. Corporate includes expenses of the Corporate function not allocated to specific business in the Company. |  |  |  |  |  |  |  |
| **Equity in Earnings of Nonconsolidated Affiliates by Segment** | *Three Months Ended* | *Three Months Ended* | *Twelve Months Ended* | *Twelve Months Ended* |  |  |  |  |  |
| In millions (Unaudited) | *Dec 31, 2025* | *Dec 31, 2024* | *Dec 31, 2025* | *Dec 31, 2024* |  |  |  |  |  |
| Healthcare & Water Technologies | $1 | $1 | $2 | $1 |  |  |  |  |  |
| Diversified Industrials |  |  | (1) |  |  |  |  |  |  |
| Corporate <sup>1</sup> | (2) | (1) | (8) | (7) |  |  |  |  |  |
| Total equity earnings included in operating EBITDA (GAAP) | $(1) | $— | $(7) | $(6) |  |  |  |  |  |
| 1. Corporate includes the equity interest acquired in the Delrin® Divestiture transaction. | 1. Corporate includes the equity interest acquired in the Delrin® Divestiture transaction. | 1. Corporate includes the equity interest acquired in the Delrin® Divestiture transaction. |  |  |  |  |  |  |  |
| **Reconciliation of "Income from continuing operations, net of tax" to "Operating EBITDA"** | *Three Months Ended* | *Three Months Ended* | *Twelve Months Ended* | *Twelve Months Ended* |  |  |  |  |  |
| **Reconciliation of "Income from continuing operations, net of tax" to "Operating EBITDA"** | *Three Months Ended* | *Three Months Ended* | *Twelve Months Ended* | *Twelve Months Ended* | In millions (Unaudited) | *Dec 31, 2025* | *Dec 31, 2024* | *Dec 31, 2025* | *Dec 31, 2024* |
| Income from continuing operations, net of tax (GAAP) | $(108) | $(291) | $98 | $(96) |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;+ Provision for income taxes on continuing operations | 42 | 92 | 102 | 213 |  |  |  |  |  |
| Income from continuing operations before income taxes | $(66) | $(199) | $200 | $117 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;+ Depreciation and amortization | 159 | 163 | 647 | 635 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;'- Interest income <sup>1, 2</sup> | 20 | 19 | 72 | 74 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;'+ Interest expense <sup>3</sup> | 61 | 84 | 311 | 365 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;'- Non-operating pension/OPEB benefit (costs) credits <sup>1</sup> | 3 | 2 | 5 | 9 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;'- Foreign exchange losses, net <sup>1</sup> | (5) | 16 | (34) | (3) |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;+ Future reimbursable indirect costs | 14 | 25 | 89 | 100 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;+ Remediation costs associated with divested businesses | 4 | 3 | 12 | 14 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;+ Significant items (charge) benefit | (255) | (356) | (412) | (380) |  |  |  |  |  |
| Operating EBITDA (non-GAAP) | $409 | $395 | $1628 | $1531 |  |  |  |  |  |

---

1. Included in "Sundry income (expense) - net".

2. The three and twelve months ended December 31, 2025 excludes accrued interest income earned on employee retention credits and interest income earned on cash held in escrow associated with the Qnity financing. Refer to details of significant items on pages 16-17.

3. The three and twelve months ended December 31, 2025 excludes interest rate swap basis amortization. Refer to details of significant items on pages 16-17.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of "Cash provided by operating activities - continuing operations" to Adjusted Free Cash Flow** <sup>1</sup> **, Transaction-Adjusted Free Cash Flow**<sup>1</sup> **and calculation of "Adjusted Free Cash Flow Conversion" and "Transaction-Adjusted Free Cash Flow Conversion"** | *Three Months Ended* | *Three Months Ended* | *Twelve Months Ended* | *Twelve Months Ended* |
| In millions (Unaudited) | *Dec 31, 2025* | *Dec 31, 2024* | *Dec 31, 2025* | *Dec 31, 2024* |
| Cash provided by operating activities (GAAP) <sup>2</sup> - continuing operations | $87 | $161 | $560 | $765 |
| Capital expenditures | (87) | (71) | (333) | (285) |
| Adjusted free cash flow (non-GAAP) | $— | $90 | $227 | $480 |
| Separation-related transaction cost and other payments<sup>3</sup> | 228 | 29 | 462 | 107 |
| Transaction-adjusted free cash flow (non-GAAP) | $228 | $119 | $689 | $587 |
| Adjusted earnings (non-GAAP) <sup>4</sup> | $193 | $165 | $704 | $613 |
| Adjusted free cash flow conversion (non-GAAP) | —% | 55% | 32% | 78% |
| Transaction-adjusted free cash flow conversion (non-GAAP) | 118% | 72% | 98% | 96% |

---

1. Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow are calculated on a continuing operations basis for all periods presented. Refer to the definitions of Non-GAAP metrics on pages 9-10 for additional information.

2. Refer to the Consolidated Statement of Cash Flows included in the schedules above for major GAAP cash flow categories as well as further detail relating to the changes in "Cash provided by operating activities - continuing operations" for the twelve month periods noted.

3. Other payments for the year ended December 31, 2025 includes $144 million for interest rate swap settlements and debt exchange fees that were related to achieving the post-spin capital structure for new DuPont, $9 million related to restructuring related compensation cash payments for certain executive officers, $16 million of separation-related capital expenditures and $70 million for Future Reimbursable Indirect Costs (as defined in our Non-GAAP definitions).

4. Refer to pages 16-17 for the Non-GAAP reconciliations of Net income from continuing operations available for DuPont common stockholders to Adjusted Earnings (Non-GAAP).

------

**DuPont de Nemours, Inc.**

**Selected Financial Information and Non-GAAP Measures**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Significant Items Impacting Results for the Three Months Ended December 31, 2025** | **Significant Items Impacting Results for the Three Months Ended December 31, 2025** | **Significant Items Impacting Results for the Three Months Ended December 31, 2025** | **Significant Items Impacting Results for the Three Months Ended December 31, 2025** | **Significant Items Impacting Results for the Three Months Ended December 31, 2025** |
| In millions, except per share amounts (Unaudited) | *Pretax* <sup>1</sup> | *Net Income* <sup>2</sup> | *EPS* <sup>3</sup> | *Income Statement Classification* |
| Reported earnings (GAAP) | $(66) | $(111) | $(0.27) |  |
| Less: Significant items |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Acquisition, integration & separation costs | (36) | (31) | (0.08) | Acquisition, integration and separation costs |
| &nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | (94) | (72) | (0.17) | Restructuring and asset related charges - net |
| &nbsp;&nbsp;Loss on debt extinguishment <sup>4</sup> | (114) | (88) | (0.21) | Sundry income (expense) - net |
| &nbsp;&nbsp;Interest rate swap mark-to-market loss <sup>5</sup> | (17) | (13) | (0.03) | Sundry income (expense) - net |
| &nbsp;&nbsp;Qnity financing <sup>6</sup> | 6 | 5 | 0.01 | Sundry income (expense) - net |
| &nbsp;&nbsp;Other benefits (credits), net <sup>7</sup> |  |  |  | Sundry income (expense) - net; Selling, general and administrative expenses |
| &nbsp;&nbsp;Income tax items <sup>8</sup> |  | (39) | (0.09) | Provision for income taxes on continuing operations |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total significant items | $(255) | $(238) | $(0.57) |  |
| Less: Amortization of intangibles | (71) | (55) | (0.13) | Amortization of intangibles |
| Less: Non-op pension / OPEB benefit costs | 3 | 3 | 0.01 | Sundry income (expense) - net |
| Less: Future reimbursable indirect costs | (14) | (11) | (0.03) | Selling, general and administrative expenses |
| Less: Corporate DDOB remediation costs | (4) | (3) | (0.01) | Selling, general and administrative expenses |
| Adjusted earnings (non-GAAP) | $275 | $193 | $0.46 |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Significant Items Impacting Results for the Three Months Ended December 31, 2024** | **Significant Items Impacting Results for the Three Months Ended December 31, 2024** | **Significant Items Impacting Results for the Three Months Ended December 31, 2024** | **Significant Items Impacting Results for the Three Months Ended December 31, 2024** | **Significant Items Impacting Results for the Three Months Ended December 31, 2024** |
| In millions, except per share amounts (Unaudited) | *Pretax* <sup>1</sup> | *Net Income* <sup>2</sup> | *EPS* <sup>3</sup> | *Income Statement Classification* |
| Reported earnings (GAAP) | $(199) | $(294) | $(0.70) |  |
| Less: Significant items |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Acquisition, integration and separation costs | (59) | (46) | (0.11) | Acquisition, integration and separation costs |
| &nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | (9) | (7) | (0.02) | Restructuring and asset related charges - net |
| &nbsp;&nbsp;Inventory write-offs <sup>9</sup> | 2 | 1 |  | Cost of sales |
| &nbsp;&nbsp;Interest rate swap mark-to-market loss <sup>10</sup> | (290) | (222) | (0.53) | Sundry income (expense) - net |
| &nbsp;&nbsp;Income tax items <sup>11</sup> |  | (106) | (0.24) | Provision for income taxes on continuing operations |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total significant items | $(356) | $(380) | $(0.90) |  |
| Less: Amortization of intangibles | (76) | (60) | (0.14) | Amortization of intangibles |
| Less: Non-op pension / OPEB benefit credits | 2 | 2 |  | Sundry income (expense) - net |
| Less: Future reimbursable indirect costs | (25) | (19) | (0.04) | Selling, general and administrative expenses |
| Less: Corporate DDOB remediation costs | (3) | (2) | (0.01) | Selling, general and administrative expenses |
| Adjusted earnings (non-GAAP) | $259 | $165 | $0.39 |  |

---

1. Income (loss) from continuing operations before income taxes.

2. Net income (loss) from continuing operations available for DuPont common stockholders. The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

3. Earnings (loss) per common share from continuing operations - diluted.

4. Includes $15 million of treasury transaction-related fees in addition to $99 million loss on debt extinguishment related to the Debt Exchange, Special Mandatory Redemption, Consent Solicitation and Tender Offer.

5. The three months ended December 31, 2025 includes the non-cash mark-to-market net loss related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps.

6. Includes interest income earned on cash held in escrow associated with the Qnity notes.

7. Reflects the accrued interest earned on employee retention credits ($5 million pre-tax), and a benefit related to an indemnification receivable for a tax matter ($3 million pre-tax) offset by legal costs within the Healthcare & Water segment associated with a pending intellectual property matter ($8 million pre-tax).

8. Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.

9. Reflects an adjustment to raw material inventory write-offs recorded in "Cost of Sales" in connection with restructuring actions related to plant line closures within the Healthcare & Water segment.

10. The three months ended December 31, 2024 includes non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps.

11. Reflects the impact of an international tax audit.

------

**DuPont de Nemours, Inc.**

**Selected Financial Information and Non-GAAP Measures**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Significant Items Impacting Results for the Twelve Months Ended December 31, 2025** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2025** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2025** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2025** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2025** |
| In millions, except per share amounts (Unaudited) | *Pretax* <sup>1</sup> | *Net Income* <sup>2</sup> | *EPS* <sup>3</sup> | *Income Statement Classification* |
| Reported losses (GAAP) | $200 | $88 | $0.21 |  |
| Less: Significant items |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Acquisition, integration & separation costs | (203) | (162) | (0.39) | Acquisition, integration and separation costs |
| &nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | (151) | (118) | (0.28) | Restructuring and asset related charges - net |
| &nbsp;&nbsp;Loss on debt extinguishment <sup>4</sup> | (114) | (88) | (0.21) | Sundry income (expense) - net |
| &nbsp;&nbsp;Interest rate swap mark-to-market gain <sup>5</sup> | 29 | 24 | 0.06 | Sundry income (expense) - net; interest expense |
| &nbsp;&nbsp;Qnity financing <sup>6</sup> | 15 | 12 | 0.03 | Sundry income (expense) - net |
| &nbsp;&nbsp;Other benefits (credits), net <sup>7</sup> | 12 | 9 | 0.01 | Sundry income (expense) - net; Selling, general and administrative expenses |
| &nbsp;&nbsp;Income tax items <sup>8</sup> |  | 7 | 0.02 | Provision for income taxes on continuing operations |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total significant items | $(412) | $(316) | $(0.76) |  |
| Less: Amortization of intangibles | (291) | (227) | (0.54) | Amortization of intangibles |
| Less: Non-op pension / OPEB benefit credits | 5 | 5 | 0.01 | Sundry income (expense) - net |
| Less: Future reimbursable indirect costs | (89) | (69) | (0.16) | Selling, general and administrative expenses |
| Less: Corporate DDOB remediation costs | (12) | (9) | (0.02) | Selling, general and administrative expenses |
| Adjusted earnings (non-GAAP) | $999 | $704 | $1.68 |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Significant Items Impacting Results for the Twelve Months Ended December 31, 2024** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2024** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2024** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2024** | **Significant Items Impacting Results for the Twelve Months Ended December 31, 2024** |
| In millions, except per share amounts (Unaudited) | *Pretax* <sup>1</sup> | *Net Income* <sup>2</sup> | *EPS* <sup>3</sup> | *Income Statement Classification* |
| Reported earnings (GAAP) | $117 | $(98) | $(0.23) |  |
| Less: Significant items |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Acquisition, integration and separation costs | (90) | (75) | (0.18) | Acquisition, integration and separation costs |
| &nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | (57) | (44) | (0.10) | Restructuring and asset related charges - net |
| &nbsp;&nbsp;Inventory write-offs <sup>9</sup> | (25) | (20) | (0.05) | Cost of sales |
| &nbsp;&nbsp;Loss on debt extinguishment <sup>10</sup> | (74) | (57) | (0.14) | Sundry income (expense) - net |
| &nbsp;&nbsp;Interest rate swap mark-to-market loss <sup>11</sup> | (139) | (104) | (0.25) | Sundry income (expense) - net; interest expense |
| &nbsp;&nbsp;Other benefits (credits), net <sup>12</sup> | (2) | (1) |  | Costs of sales |
| &nbsp;&nbsp;Income tax items <sup>13</sup> | 7 | (99) | (0.23) | Sundry income (expense) - net; Provision for income taxes on continuing operations |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total significant items | $(380) | $(400) | $(0.95) |  |
| Less: Amortization of intangibles | (294) | (231) | (0.55) | Amortization of intangibles |
| Less: Non-op pension / OPEB benefit credits | 9 | 7 | 0.02 | Sundry income (expense) - net |
| Less: Future reimbursable indirect costs | (100) | (77) | (0.18) | Selling, general and administrative expenses |
| Less: Corporate DDOB remediation costs | (14) | (10) | (0.02) | Selling, general and administrative expenses |
| Adjusted earnings (non-GAAP) | $896 | $613 | $1.45 |  |

---

1. Income (loss) from continuing operations before income taxes.

2. Net income (loss) from continuing operations available for DuPont common stockholders. The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

3. Earnings (loss) per common share from continuing operations - diluted.

4. Includes $15 million of treasury transaction-related fees in addition to $99 million loss on debt extinguishment related to the Debt Exchange, Special Mandatory Redemption, Consent Solicitation and Tender Offer.

5. The twelve months ended December 31, 2025 includes the non-cash mark-to-market net gain related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps. The year ended December 31, 2025 also includes basis amortization on the 2022 Swaps ($2 million pre-tax, reflected in "Interest expense" within the Consolidated Statements of Operations).

6. Includes interest income earned on cash held in escrow associated with the Qnity notes.

7. Reflects benefits related to an adjustment of the Donatelle contingent earn-out liability ($19 million pre-tax), accrued interest earned on employee retention credits ($11 million pre-tax), a benefit related to an indemnification receivable for a tax matter ($3 million pre-tax) offset by legal costs within the Healthcare & Water segment associated with a pending intellectual property matter ($22 million pre-tax).

8. Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.

9. Reflects net raw material inventory write-offs recorded in "Cost of Sales" in connection with restructuring actions related to plant line closures within the Healthcare & Water segment.

10. Reflects the loss on extinguishment of debt related to the partial redemption of the 2038 notes.

11. The year ended December 31, 2024 includes non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps. The year ended December 31, 2024 also includes basis amortization on the 2022 Swaps ($1 million pre-tax, reflected in "Interest expense" within the Consolidated Statements of Operations).

12. Reflects credit for the amortization of an inventory step-up adjustment related to the Donatelle Plastics acquisition ($2 million pre-tax).

13. Reflects the impact of an international tax audit.

<br>